INFO,Title,Nasopharyngeal Carcinoma (NPC) Data Dictionary,,,,,,,,,
INFO,Name,npc_v1.0,,,,,,,,,
INFO,Release Notes,,,,,,,,,,
INFO,Parent Model,pcdc_v2.0,,,,,,,,,
INFO,License,Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/),,,,,,,,,
INFO,Modeling Wiki,https://docs.pedscommons.org/,,,,,,,,,
INFO,Consortium Info,https://commons.cri.uchicago.edu/pcdc/,,,,,,,,,
INFO,Description,,,,,,,,,,
INFO,Total Variables,,,,,,,,,,
,,,,,,,,,,,
RowType,VariableName,DataType,Tier,VariableDescription,VariableCode,PermissibleValue,ValueDescription,ValueCode,ImplementationNotes,Mappings,Modeling notes (Will be ignored in processing)
,,,,,,,,,,,
DD,Protocol,,,,,,,,,,
TD,Subject Characteristics,,Mandatory,,,,,,,,
TG,One row per subject per study,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,CONSORTIUM,Enum,Mandatory,The consortium under which this data is being contributed to the Pediatric Cancer Data Commons.,ncit:C61538,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,NOBLE,Nasopharyngeal Carcinoma Global Partnership,,,,
VD,DATA_CONTRIBUTOR_ID,Enum,Mandatory,An identifier assigned to a data contributor.,ncit:C168950,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,COG,"Children's Oncology Group. An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.",ncit:C39353,,,
PD,,,,,,EXPeRT,The European Cooperative Study Group for Pediatric Rare Tumors.,,,,
PD,,,,,,GPOH,"German Society for Pediatric Oncology and Hematology. A research organization in Germany involved in the understanding, diagnosis, treatment and prognosis of pediatric cancers.",ncit:C174960,,,
PD,,,,,,ISPHO,Israel Society of Pediatric Hematology and Oncology,,,,
PD,,,,,,Tata Memorial Centre,,,,,
PD,,,,,,TROD,Turkish Society for Radiation Oncology,,,,
VD,STUDY_ID,Enum,Mandatory,"A sequence of characters used to identify, name, or characterize the study.",ncit:C83082,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,ARAR0331,"Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer. This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as amifostine, may protect normal cells from the side effects of radiation therapy. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with amifostine and chemotherapy may kill more tumor cells. (ClinicalTrials.gov Identifier: NCI-2009-00412)",,,,"Mark K (retired), COG statistician (?)"
PD,,,,,,GPOH: 2011-17,,,,,GPOH
PD,,,,,,NPC 2016 registry,,,,,GPOH
PD,,,,,,NPC-91,,,,,GPOH
PD,,,,,,TATA,,,,,What's the name for their registry? Use unique study_id for this disease group.
PD,,,,,,ISPHO,,,,,
PD,,,,,,TROD1,,,,,
VD,AGE_AT_ENROLLMENT,Integer,Priority,The age (in days) when the subject enrolled in the study.,ncit:C168843,_undefined_,_undefined_,_undefined_,"ConditionalStatement: if 'ENROLLED_STATUS' == 'Enrolled' | ConditionalStatement: Mandatory if ""AGE_AT_DIAG_ASSESSMENT"" is null.",,not prospecitve data so will not have treatment arm
VD,EFS_CENSOR_STATUS,Enum,Priority,"The status of individuals in a study when their outcome (event occurrence or time to event) is censored or not censored at the time of analysis or data collection. Censoring occurs when an individual has not experienced the event of interest by the end of the study period or at the time of data analysis, often because they were lost to follow-up, withdrew from the study, or the study ended before the event could occur. In event-free survival analysis, these censored individuals are included in the analysis up to the point of censoring and are essential for estimating survival probabilities and analyzing the time to events.",,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Censored,The status of a participant or subject in a study whose event or outcome of interest has not yet occurred or has not been observed within the study's follow-up period. Censoring occurs when the event of interest has not happened to a participant by the end of the study or when they are lost to follow-up before the event occurs.,ncit:C118962,,,
PD,,,,,,Not Censored,"The patient has experienced the event of interest within the study period and has reached the endpoint being evaluated, such as disease progression, relapse, recurrence, or death, and their time to event can be accurately recorded and analyzed.",,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,AGE_AT_CENSOR_STATUS,Integer,Priority,The age (in days) of the subject at the time of the event censor status.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: if 'EFS_CENSOR_STATUS' not null.,,
VD,TREATMENT_ARM,Enum,Optional,A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.,ncit:C15538,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Cisplatine + 5FU,,,,,
PD,,,,,,Docetaxel + Cisplatin + 5FU,,,,,
PD,,,,,,Bleomycin-Doxurubicin-Cisplatin (BAC),,,,,
PD,,,,,,Cisplatin-Docetaxel,,,,,
VD,AGE_AT_TXASSIGN,Integer,Optional,The age (in days) when the subject was assigned to a treatment arm.,ncit:C175529,_undefined_,_undefined_,_undefined_,,,
VD,ENROLLED_STATUS,Enum,Optional,"This variable indicates if the subject was enrolled in the study, or if the subject was not enrolled in the study but received treatment per the study's protocol.",ncit:C168928,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Enrolled,The study subject is enrolled.,ncit:C142715,,,
PD,,,,,,Not Enrolled,The study subject is not enrolled.,ncit:C168929,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,YEAR_AT_ENROLLMENT,Integer,Optional,The year at which a subject enrolled in a study.,ncit:C177353,_undefined_,_undefined_,_undefined_,ConditionalStatement: if 'ENROLLED_STATUS' == 'Enrolled'.,,
VD,DATA_SOURCE,Enum,Optional,"Source of information collected in the course of a clinical trial, specifically used to differentiate between data as collected versus data that are derived or calculated.",ncit:C16493,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Registry,"Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)",ncit:C129000,"ConsortiumNotes: For TROD, use Registry only.",,
PD,,,,,,Therapeutic Trial,"A clinical study that involves administering of exposure to the agent/agents to subjects with particular disease to elucidate the most appropriate treatment for a specific medical condition, or to prolong or improve the patient's life.",ncit:C39536,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,STUDY_PHASE,Enum,Optional,The phase of the clinical trial that the subject was enrolled in for the collection of this data.,ncit:C48281,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Pilot,The initial study examining a new method or treatment.,ncit:C15303,,,
PD,,,,,,Phase 1,A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.,ncit:C15600,,,
PD,,,,,,Phase 2,"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.",ncit:C15601,,,
PD,,,,,,Phase 3,"A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.",ncit:C15602,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,STUDY_TYPE,Enum,Optional,"Source of information collected in the course of a clinical trial, specifically used to differentiate between data as collected versus data that are derived or calculated.",ncit:C142175,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Frontline,A clinical trial for previously untreated patients that studies the use of a first line of treatment.,ncit:C185306,,,
PD,,,,,,Retrieval,A trial to assess the efficacy of reinduction therapy.,ncit:C185307,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Protocol,,,,,,,,,,
TD,Time Period,,Priority,,,,,,ConditionalStatement: Implement as needed,,
TG,One row per subject per time period type,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,SUBMITTER_ID,String,Mandatory,An ID provided by the data contributor that identifies a unique time period and that is referenced throughout subsequent tabels in the TIME_PERIOD_SUBMITTER_ID variables.,,_undefined_,_undefined_,_undefined_,,,
VD,PARENT_SUBMITTER_ID,String,Mandatory,"The SUBMITTER_ID of the time period in whose context a subsequent time period takes place. For example, multiple treatment courses occuring the ""Initial Diagnosis"" period would each reference the SUBMITTER_ID of the ""Initial Diagnosis"" period as their PARENT_SUBMITTER_ID.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'TIME_PERIOD_TYPE' == 'Course'.,,
VD,TIME_PERIOD_TYPE,Enum,Mandatory,The type of time period being reported.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Disease Phase,The stage or period of an individual's disease.,ncit:C168878,,,
PD,,,,,,Course,The type of protocol treatment course administered with respect to Course Timing.,ncit:C187095,,,
VD,DISEASE_PHASE,Enum,Mandatory,"The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see ""Disease Phase Timing and Course Table"" in the documentation for additional guidance).",ncit:C168878,_undefined_,_undefined_,_undefined_,"ConditionalStatement: If 'TIME_PERIOD_TYPE' == 'Disease Phase' | ConsortiumNote: For COG initial MB data, all will be initial diagnosis.",,
PD,,,,,,Initial Diagnosis,The first diagnosis of the individual's condition.,ncit:C156813,,,
PD,,,,,,Relapse,The return of a disease after a period of remission.,ncit:C38155,,,
PD,,,,,,Progression,A process that manifests as the worsening of a disease over time.,ncit:C17747,,,
PD,,,,,,Refractory/Progression,Either the return of the disease or the progression of the disease.,ncit:C174991,,,
VD,COURSE,Enum,Mandatory,"The protocol treatment ""course"" during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see ""Disease Phase Timing and Course Table"" in the documentation for additional guidance).",ncit:C168807,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'TIME_PERIOD_TYPE' == 'Course'.,,
PD,,,,,,Induction,The first choice of treatment for a particular type of cancer.,ncit:C158876,,,
PD,,,,,,Concomitant Chemoradiation Therapy,,,ConsortiumNotes: Specifically for TROD data.,New PD,
PD,,,,,,Consolidation,Treatment that is given after initial therapy to kill any remaining cancer cells.,ncit:C15679,"ConsortiumNote: Use for frontline treatment (initial diagnosis): Radiotherapy alone, Chemoradiotherapy + Immunotherapy.",,
PD,,,,,,Maintenance,Continuation of treatment for an extended period of time to prevent relapse.,ncit:C15688,,,
PD,,,,,,"Chemotherapy, NOS",The use of synthetic or naturally-occurring chemicals for the treatment of diseases.,ncit:C15632,ConsortiumNote: Only when DISEASE_PHASE = 'Relapse'.,,
PD,,,,,,Radiation Therapy,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,ncit:C15313,ConsortiumNote: Only when DISEASE_PHASE = 'Relapse'.,,
PD,,,,,,Immunotherapy,Therapy designed to induce changes in a patient's immune status in order to treat disease.,ncit:C15262,ConsortiumNote: Only when DISEASE_PHASE = 'Relapse'.,,
VD,TIME_PERIOD_NUMBER,Integer,Mandatory,"This variable indicates the ordinal numbering of time periods of the same TIME_PERIOD_TYPE within its various subgroups (e.g., Relapse 1, Relapse 2, Relapse 3, etc.). The observations across domains can therefore be organized longitudinally without the need for specific dates.",,_undefined_,_undefined_,_undefined_,,,
VD,YEAR_AT_START,Integer,Priority,The year at the start of the indicated time period.,,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_START,Integer,Mandatory,The age (in days) of the patient at the start of the reported time period.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'TIME_PERIOD_TYPE' is not null.,,
VD,AGE_AT_END,Integer,Optional,The age (in days) of the patient at the end of the reported time period.,,_undefined_,_undefined_,_undefined_,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Protocol,,,,,,,,,,
TD,Off Protocol Therapy Or Study,,Optional,,,,,,,,
TG,One row per subject per off protocol therapy or study per reason off,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_OFF,Integer,Mandatory,The age (in days) when the subject went off of the protocol therapy or study.,ncit:C168844,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,OFF_TYPE,Enum,Priority,Did the subject go off of a study or off of a certain protocol therapy?,ncit:C173256,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Protocol Therapy,No longer receiving protocol therapy.,ncit:C173257,,,
PD,,,,,,Study,No longer participating in a study; not being followed and will not be retreated.,ncit:C29851,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,REASON_OFF,Enum,Priority,The reason a subject went off the therapy or study.,ncit:C173519,_undefined_,_undefined_,_undefined_,"ConsortiumNote: If multiple reasons off ""protocol therapy"" or ""study"", include one observation per reason.",,
PD,,,,,,Death,Specifies whether the life of an entity has ceased.,ncit:C28554,,,
PD,,,,,,Lost to Follow-Up,The subject was not available for follow-up procedures.,ncit:C70740,,,
PD,,,,,,Completion of Planned Therapy,The end of the planned treatment.,ncit:C168935,,,
PD,,,,,,Physician Decision,"A position, opinion or judgment reached after consideration by a physician with reference to subject.",ncit:C48250,,,
PD,,,,,,Withdrawal of Consent,When the permission to do something is rescinded or withdrawn.,ncit:C48271,,,
PD,,,,,,Subject/Guardian Refused Further Treatment,The subject or their guardian has refused further treatment.,ncit:C168934,,,
PD,,,,,,Disease Progression,The worsening of a disease over time.,ncit:C17747,,,
PD,,,,,,Secondary Malignancy,"A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.",ncit:C4968,,,
PD,,,,,,Toxicity,The finding of bodily harm due to the poisonous effects of something.,ncit:C27990,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,REASON_OFF_OTHER,String,Optional,"Specify the ""Other"" REASON_OFF.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'REASON_OFF' == 'Other'.,,
VD,ANOTHER_STUDY,Enum,Optional,Did the subject enroll in another study after they went off of the study indicated by OFF_TYPE?,ncit:C178073,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Demographics,,,,,,,,,,
TD,Demographics,,Priority,,,,,,,,
TG,One row per subject,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,SEX,Enum,Mandatory,The biological sex of the subject.,ncit:C28421,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Male,"A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.",ncit:C20197,,,
PD,,,,,,Female,"A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.",ncit:C16576,,,
PD,,,,,,Undifferentiated,Sex could not be determined; not uniquely defined; undifferentiated.,ncit:C41438,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,RACE,Enum,Optional,A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.,ncit:C17049,_undefined_,_undefined_,_undefined_,,,Usually no data from Europeans
PD,,,,,,American Indian or Alaska Native,A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment. (OMB),ncit:C41259,,,
PD,,,,,,Asian,"A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (OMB)",ncit:C41260,,,
PD,,,,,,Black or African American,"A person having origins in any of the Black racial groups of Africa. Terms such as ""Haitian"" or ""Negro"" can be used in addition to ""Black or African American"". (OMB)",ncit:C16352,,,
PD,,,,,,Multiracial,Having ancestors of several or various races.,ncit:C67109,,,
PD,,,,,,Native Hawaiian or Other Pacific Islander,"A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. (OMB)",ncit:C41219,,,
PD,,,,,,White,"A person having origins in any of the original peoples of Europe, the Middle East, or North Africa. (OMB)",ncit:C41261,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,RACE_OTHER,String,Optional,"Specify the ""Other"" RACE.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RACE' == 'Other'.,,
VD,ETHNICITY,Enum,Optional,"The social and cultural characteristics, backgrounds, or experiences shared by a group of people. These include language, religion, beliefs, values, and behaviors that are often handed down from one generation to the next. Some conditions or diseases, such as cancer, may be more common in certain ethnic groups than in others. (Source: NCI Dictionary of Cancer Terms)",ncit:C16564,_undefined_,_undefined_,_undefined_,,,MW: ISPHO - which additional ethnicities are required?
PD,,,,,,Hispanic or Latino,"A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term, ""Spanish origin,"" can be used in addition to ""Hispanic or Latino."" (OMB)",ncit:C17459,,,
PD,,,,,,Not Hispanic or Latino,"A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.",ncit:C41222,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Demographics,,,,,,,,,,
TD,Family Medical History,,Optional,,,,,,,,
TG,One row per subject per family member per cancer type,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,CONDITION_STATUS,Enum,Mandatory,Does the relation have a medical history that includes cancer?,ncit:C17726,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,RELATION,Enum,Priority,What kind of relation is this relative who has had a relevant medical condition?,ncit:C21480,_undefined_,_undefined_,_undefined_,,,Add more relations? (second degree relatives and other)
PD,,,,,,Father,A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm.,ncit:C96572,,,
PD,,,,,,Mother,A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum.,ncit:C96580,,,
PD,,,,,,Brother,A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents.,ncit:C96570,,,
PD,,,,,,Sister,A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents.,ncit:C96586,,,
PD,,,,,,Son,A male progeny with genetic makeup inherited from the parent.,ncit:C150888,,,
PD,,,,,,Daughter,A female progeny with genetic makeup inherited from the parent.,ncit:C150887,,,
PD,,,,,,"First-Degree Relative, NOS",,,,,
VD,CONDITION,String,Priority,The type of prior cancer from the medical history of the relative of the subject.,ncit:C185318,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'PRIOR_CANCER' == 'Yes'.,,"Per TROD, should we only report data where family only has NPC? Ask EC."
,,,,,,,,,,,
,,,,,,,,,,,
DD,Demographics,,,,,,,,,,
TD,Medical History,,Optional,,,,,,,,"Per TROD, need AGE_AT_CONDITION?"
TG,One row per subject per prior medical history,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,CONDITION_STATUS,Enum,Mandatory,Was this condition observed in the subject?,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'CONDITION' not null.,,"Per TROD, this seems irrelevant to have 'No' because there are too many CONDITION"
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,CONDITION,Enum,Mandatory,Relevant condition from the subject's medical history.,ncit:C18772,_undefined_,_undefined_,_undefined_,"D4CGNote: If subject had multiple prior medical conditions, include one observation per condition.",,
PD,,,,,,Adenomatous Polyposis Coli,"Adenomatous polyposis coli protein (2843 aa, ~312 kDa) is encoded by the human APC gene. This protein is involved in both tumor suppression and the inhibition of the Wnt signaling pathway.",ncit:C17687,,,
PD,,,,,,Adrenocortical Carcinoma / Adenoma,,,,,
PD,,,,,,ALL (Low Hypodiploid),,,,,
PD,,,,,,ALL (Ringed Chromosome 21),,,,,
PD,,,,,,ALL (Robertsonian translocation 15;21),,,,,
PD,,,,,,ALL Relapse (TP53 mutated),,,,,
PD,,,,,,AML (Monosomy 7),,,,,
PD,,,,,,Basal Cell Carcinoma,,,,,
PD,,,,,,Beckwith-Wiedemann Syndrome,"A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, Rhabdomyosarcoma) and adrenal cortex carcinomas.",ncit:C34415,,,
PD,,,,,,Bloom Syndrome,"Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells.",ncit:C2903,,,
PD,,,,,,Botryoid Rhabdomyosarcoma Of The Urogenital Tract (Fusion-Negative),,,,,
PD,,,,,,Breast and Ovarian Cancer,"An autosomal dominant inherited syndrome caused by mutations in the BRCA1 or BRCA2 genes. Patients are at high risk of developing breast cancer, particularly before the age of fifty, high risk of developing a second primary breast cancer, and high risk of developing both breast and ovarian cancer.",ncit:C8493,,,
PD,,,,,,Celiac Disease,"An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.",ncit:C26714,,,
PD,,,,,,Central Hypoventilation Syndrome,A disorder characterized by hypoventilation and hypoxemia. It appears early in life and is not associated with cardiopulmonary or neuromuscular abnormalities.,ncit:C98889,,,
PD,,,,,,Cherubism,"A rare autosomal dominant inherited disorder usually caused by mutations in the SH3BP2 gene. It is characterized by a prominent lower part of the face due to bilateral replacement of the mandibular or maxillary bones by tumors. The tumors contain osteoclast-like cells admixed with spindle-shaped mononuclear stromal cells. With time, the tumors become more fibrotic and less osteoclast-rich.",ncit:C84630,,,
PD,,,,,,Chondromesenchymal Harmatoma,,,,,
PD,,,,,,Choroid Plexus Carcinoma / Tumor,,,,,
PD,,,,,,Cleft Lip,"A congenital abnormality consisting of one or more clefts (splits) in the upper lip, which may be accompanied by a cleft palate; it is the result of the failure of the embryonic parts of the lip to fuse.",ncit:C87175,,,
PD,,,,,,Cleft Palate,A congenital abnormality consisting of a fissure in the midline of the hard and/or soft palate; it is the result of the failure of the two sides of the palate to fuse during embryonic development.,ncit:C87069,,,
PD,,,,,,Clubfoot,"The most common congenital deformation of the foot, occurring in 1 of 1,000 live births. The most common form is talipes equinovarus, where the deformed foot is turned downward and inward sharply.",ncit:C84641,,,
PD,,,,,,Colorectal Carcinoma,,,,,
PD,,,,,,Costello Syndrome,"A genetic syndrome caused by mutations in the HRAS gene. It is characterized by developmental delay, mental retardation, loose skin folds, cardiomyopathy, tachycardia, and structural heart defects. Patients are at an increased risk of developing benign or malignant neoplasms.",ncit:C84652,,,
PD,,,,,,Cranial Nerve Palsy,,,,,
PD,,,,,,Cushings Syndrome,"A syndrome caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids secondary to pituitary or adrenocortical neoplasms, or intake of glucocorticoid drugs. Signs and symptoms include a round face, upper body obesity, fragile and thin skin, purple stretch marks in the skin, fatigue, muscle weakness, hypertension, diabetes mellitus, hypertrichosis and amenorrhea in women, impotence in men, and osteoporosis.",ncit:C2969,,,
PD,,,,,,Cystic Nephroma,,,,,
PD,,,,,,Denys-Drash Syndrome,"A rare congenital syndrome caused by mutations in the WT1 gene. It is characterized by the presence of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor, and intersex disorders.",ncit:C84668,,,
PD,,,,,,Diabetes Mellitus (Type I),A chronic condition characterized by minimal or absent production of insulin by the pancreas.,ncit:C2986,,,
PD,,,,,,Diamond-Blackfan Anemia,An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.,ncit:C61236,,,
PD,,,,,,DICER1 Syndrome,"A rare, autosomal dominant inherited syndrome caused by mutations in the DICER1 gene. People with this syndrome are at an increased risk of developing pleuropulmonary blastoma, cystic nephroma, Sertoli-Leydig cell tumor of the ovary, and multinodular goiter.",ncit:C123317,,,
PD,,,,,,Down Syndrome,"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.",ncit:C2993,,,
PD,,,,,,Endolymphatic Sack Tumor,,,,,
PD,,,,,,Epistaxis,,,,,
PD,,,,,,Fanconi Anemia,"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.",ncit:C62505,,,
PD,,,,,,Fetal Rhabdomyoma,,,,,
PD,,,,,,Frasier Syndrome,"A condition, which typically presents during adolescence, that is caused by WT-1 mutation, and is characterized by a developmental sex disorder, FSGS, and may be associated with gonadoblastoma.",ncit:C122805,,,
PD,,,,,,Gardner Syndrome,"A variant of familial adenomatous polyposis. It is an autosomal dominant syndrome characterized by multiple colonic polyps predisposing to carcinoma of the colon, osteomas of the skull, epidermoid cysts, and fibromas. It is associated with mutation of the APC gene.",ncit:C6728,,,
PD,,,,,,Gastrointestinal Stromal Tumor,,,,,
PD,,,,,,Gastroschisis,A congenital birth defect characterized by the exposure of the fetal intestines outside the abdominal wall through an abdominal wall opening.,ncit:C84725,,,
PD,,,,,,Glioma of the Optic Pathway (With Signs of NF1),,,,,
PD,,,,,,Gonadal Dysgenesis,A congenital disorder characterized by the presence of extremely hypoplastic gonads preventing the development of secondary sex characteristics,ncit:C61420,,,
PD,,,,,,Gonadoblastoma,,,,,
PD,,,,,,Goodpasture's Syndrome,An autoimmune disorder characterized by pulmonary hemorrhage and glomerulonephritis. It is a hypersensitivity reaction resulting in the formation of antibodies against the pulmonary alveoli and the basement membrane of the glomeruli.,ncit:C34649,,,
PD,,,,,,Gorlin Syndrome,"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.",ncit:C2892,,,
PD,,,,,,Graves' Disease,"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secrets increased amounts of thyroid hormones.",ncit:C3071,,,
PD,,,,,,Hashimoto's Thyroiditis,An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.,ncit:C27191,,,
PD,,,,,,Headache,,,,,
PD,,,,,,Hearing Problems,,,,,
PD,,,,,,Heart Defect,Genetic anomalies and collections of malformations that are known to cluster together that can be associated with congenital heart defects.,ncit:C168217,,,
PD,,,,,,Hemangioblastoma,,,,,
PD,,,,,,Hemihypertrophy,A finding indicating the presence of greater than normal asymmetry between the right and left sides of the body. The asymmetry may be manifested in the entire side or part of it.,ncit:C88541,,,
PD,,,,,,Hepatoblastoma (CTNNB1 Wildtype),,,,,
PD,,,,,,Hepatocellular Carcinoma,,,,,
PD,,,,,,Hereditary Retinoblastoma,"An inherited malignant tumor that originates in the nuclear layer of the retina. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.",ncit:C8495,,,
PD,,,,,,Hirschprung Disease,A congenital disorder characterized by the absence of myenteric ganglion cells in the distal colon. It results in a functional stenosis of the distal colon and a massive distention of the proximal colon.,ncit:C34700,,,
PD,,,,,,Infantile Myofibromatosis,,,,,
PD,,,,,,Inflammatory Bowel Disease,"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.",ncit:C3138,,,
PD,,,,,,Juvenile Idiopathic Arthritis,"A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.",ncit:C114357,,,
PD,,,,,,Juvenile Myelomonocytic Leukemia,,,,,
PD,,,,,,Keratocystic Odontogenic Tumor,,,,,
PD,,,,,,Klinerfelter Syndrome,A sex chromosome disorder caused by the presence of an extra X chromosome in the male karyotype. Affected individuals are infertile and have a small penis and testes. They tend to have tall stature and long legs and may have difficulties with speech and language development. Gynecomastia may be present.,ncit:C34752,,,
PD,,,,,,Large Cell Calcifying Sertoli-cell-tumor,,,,,
PD,,,,,,Li-Fraumeni Syndrome,"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.",ncit:C3476,,,
PD,,,,,,Lymph Node Swelling,,,,,
PD,,,,,,Lynch Syndrome,"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the tumors arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.",ncit:C8494,,,
PD,,,,,,Maffucci Syndrome,A rare non-inherited disorder primarily affecting the skin and skeletal system. It is classified as a mesodermal dysplasia. Clinical signs appear within the first decade and are characterized by multiple soft tissue hemiangiomas and enchondromas leading to skeletal deformities. Clinical course is progressive with variable development of associated malignancies.,ncit:C3213,,,
PD,,,,,,Malignant Peripheral Nerve Sheath Tumor,,,,,
PD,,,,,,McCune-Albright Syndrome,"A syndrome characterized by the presence of polyostotic fibrous dysplasia, cafe-au-lait skin tumors, and sexual precocity. It is caused by mutations within the GNAS genetic locus.",ncit:C48627,,,
PD,,,,,,Medullary Renal Cell Carcinoma,,,,,
PD,,,,,,Medullary Thyroid Carcinoma,,,,,
PD,,,,,,Medulloblastoma (Shh Activated),,,,,
PD,,,,,,"Medulloblastoma (Wnt Activated, Ctnnb1 Wildtype)",,,,,
PD,,,,,,Medulloepithelioma,,,,,
PD,,,,,,Melanoma,"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.",ncit:C3224,,,
PD,,,,,,Meningioma,,,,,
PD,,,,,,Mixed Connective Tissue Disease,"An autoimmune overlap syndrome characterized by the presence of symptoms of systemic lupus erythematosus, systemic scleroderma, and polymyositis.",ncit:C84892,,,
PD,,,,,,Multiple Osteochondromas,"An autosomal dominant neoplastic chondrogenic process affecting multiple sites. It is caused by mutations in the EXT1 or EXT2 genes. Grossly and microscopically, the lesions resemble an osteochondroma.",ncit:C53457,,,
PD,,,,,,Multiple Sclerosis,A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.,ncit:C3243,,,
PD,,,,,,Myelodysplastic Syndrome,,,,,
PD,,,,,,Myeloproliferative Neoplasms (except CML),,,,,
PD,,,,,,Myxoma,,,,,
PD,,,,,,Nasal Obstruction,,,,,
PD,,,,,,Neuroendocrine Tumor,,,,,
PD,,,,,,Neurofibromatosis Type 1,"The most common type of neurofibromatosis. It is characterized clinically by cutaneous and subcutaneous tumors with patches of hyperpigmentation. The hyperpigmented skin areas, are present from birth and found anywhere on the body surface. They can vary markedly in size and color. The dark brown areas are called cafe-au-lait spots. The multiple cutaneous and subcutaneous tumors are nerve sheath tumors, called neurofibromas. They can develop anywhere along the peripheral nerve fibers. Neurofibromas can become quite large, causing a major disfigurement, eroding bone, and compressing various peripheral nerve structures. Type 1 neurofibromatosis has dominant inheritance, with a gene locus on the proximal long arm of chromosome 17.",ncit:C3273,,,
PD,,,,,,Neurofibromatosis Type 2,"An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene. It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.",ncit:C3274,,,
PD,,,,,,Noonan Syndrome,"A genetic syndrome caused by mutations in the PTPN11 gene (over 50% of the cases) or less frequently mutations in the SOS1, RAF1, or KRAS genes. It is characterized by short stature, webbed neck, hypertelorism, low-set ears, deafness, and thrombocytopenia or abnormal platelet function.",ncit:C34854,,,
PD,,,,,,Ollier Disease,"A rare benign disorder characterized by lack of normal endochondral ossification, and the growth of multiple enchondromas. It primarily affects the bones of the hand, in children and young adults. Extent of the disease varies; in some cases, neoplastic involvement may be widespread causing considerable deformity.",ncit:C3008,,,
PD,,,,,,Paget Disease,"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells). Paget cell neoplasms include Paget disease of the nipple and extramammary Paget disease which may affect the vulva, penis, anus, skin and scrotum.",ncit:C7073,,,
PD,,,,,,Paraganglioma / Pheochromocytoma,,,,,
PD,,,,,,Parathyroid Carcinoma / Adenoma,,,,,
PD,,,,,,Pineoblastoma,,,,,
PD,,,,,,Pituitary Adenoma / Tumor,,,,,
PD,,,,,,Pituitary Blastoma,,,,,
PD,,,,,,Pleuropulmonary Blastoma,,,,,
PD,,,,,,Psoriasis,"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.",ncit:C3346,,,
PD,,,,,,RB Transcriptional Corepressor 1,"The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma.",ncit:C17360,,,
PD,,,,,,Renal Cell Carcinoma,,,,,
PD,,,,,,Retinoblastoma,"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.",ncit:C7541,,,
PD,,,,,,Rhabdoid Tumor,,,,,
PD,,,,,,Rhabdomyosarcoma with Diffuse Anaplasia,,,,,
PD,,,,,,Rothmund-Thomson Syndrome,"An autosomal recessive inherited syndrome usually caused by mutations in the RECQL4 gene. It is characterized by poikilodermatous skin changes, sparse hair, cataracts, small stature, skeletal abnormalities, and an increased predisposition to cancer, particularly osteosarcoma.",ncit:C3335,,,
PD,,,,,,Schwannoma,,,,,
PD,,,,,,Schwannomatosis,Rare genetic disorder caused by mutations in the SMARCB1 and LZTR1 genes. It is characterized by the presence of multiple Schwannomas.,ncit:C6557,,,
PD,,,,,,Scleroderma,"A localized or systemic chronic and progressive autoimmune disorder characterized by thickening of the skin and the connective tissues. Localized scleroderma affects only the skin. Systemic scleroderma affects internal organs, including the heart, lungs, gastrointestinal tract, and kidneys.",ncit:C26746,,,
PD,,,,,,"Secondary Malignancy, NOS","A malignant neoplasm that arises from a pre-existing lower grade lesion/tumor, or as a result of a primary lesion/tumor that has spread to secondary sites, or due to a complication of a cancer treatment.",ncit:C4968,,,
PD,,,,,,Sertoli-Leydig Cell Tumor,,,,,
PD,,,,,,Sex Cord Stromal Tumor With Annular Tubules,,,,,
PD,,,,,,Small Cell Carcin Of The Ovary Hypercalcemic Type,,,,,
PD,,,,,,Squamous Cell Carcinoma,,,,,
PD,,,,,,Subependymal Giant Cell Astrocytoma,,,,,
PD,,,,,,Swyer Syndrome,A rare syndrome characterized by the presence of a small lung as a result of unilateral post-infectious bronchiolitis obliterans.,ncit:C85178,,,
PD,,,,,,Systematic Lupus Erythematosus,An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.,ncit:C3201,,,
PD,,,,,,Thyroid Carcinoma (Non-Medullary),,,,,
PD,,,,,,Transient Myeloproliferative Disease,,,,,
PD,,,,,,Trisomy 21,A chromosomal abnormality consisting of the presence of a third copy of chromosome 21 in somatic cells.,ncit:C43224,,,
PD,,,,,,Trisomy 21 Mosaicism,The presence of cells with and without three copies of chromosome 21 in either somatic or germinal tissue.,ncit:C142099,,,
PD,,,,,,Turner Syndrome,"A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the absence of a part or all of one of the sex chromosomes. Signs and symptoms include short stature, webbing of neck, low-set ears, hypogonadism, and sterility.",ncit:C26900,,,
PD,,,,,,Vitiligo,Generalized well circumscribed patches of leukoderma that are generally distributed over symmetric body locations and is due to autoimmune destruction of melanocytes.,ncit:C26915,,,
PD,,,,,,WAGR Syndrome,"A very rare congenital condition involving the complex of Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation. Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation (WAGR) syndrome involves deletions of several adjacent genes in chromosome region 11p13. Two or more of the four conditions must be present for an individual to be diagnosed with WAGR Syndrome. The clinical picture varies, depending upon the combination of abnormalities.",ncit:C3718,,,
PD,,,,,,Werner Syndrome,"A rare, autosomal recessive syndrome caused by mutations in the WRN gene. It is characterized by the appearance of accelerated aging following puberty. It is associated with the development of diabetes mellitus, atherosclerosis, cataracts, and cancer.",ncit:C3447,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Demographics,,,,,,,,,,
TD,Survival Characteristics,,Priority,,,,,,,,
TG,One row per last known survival status if subject is alive or cause of death if patient is deceased,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_LKSS,Integer,Mandatory,The age (in days) when the last known survival status of the subject was captured.,ncit:C168844,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,LKSS,Enum,Mandatory,The last known survival status of the subject.,ncit:C168931,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Alive,Showing characteristics of life; displaying signs of life.,ncit:C37987,,,
PD,,,,,,Dead,The cessation of life.,ncit:C28554,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,LKSS_WITH_DISEASE,Enum,Optional,Did the subject still have measurable/evaluable disease at the LKSS?,ncit:C178074,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,CAUSE_OF_DEATH,Enum,Optional,The circumstance or condition that results in the death of a living being.,ncit:C81239,_undefined_,_undefined_,_undefined_,"D4CGNote: If multiple causes of death, include one observation per cause of death. However, only one cause of death can have the varaiable CAUSE_OF_DEATH_RANKING=Primary | ConditionalStatement: If 'LKSS' is 'Dead'.",,
PD,,,,,,Disease Progression,An indication that the subject has died due to the progression of their disease.,ncit:C168970,,,
PD,,,,,,Post-Treatment Disease Complications,A complication of the disease that occurred after treatment.,ncit:C168877,,,ML: Same as infection? Toxicity?
PD,,,,,,Treatment-Related Mortality,A death that is considered to be causally linked to a treatment.,ncit:C166165,D4CGNote: Use the Adverse Events table for any additional details. Do not use CAUSE_OF_DEATH_DETAIL.,,
PD,,,,,,Secondary Malignancy,"A malignant neoplasm that arises from a pre-existing lower grade lesion/tumor, or as a result of a primary lesion/tumor that has spread to secondary sites, or due to a complication of a cancer treatment.",ncit:C4968,D4CGNote: Use the Subsequent Malignant Neoplasm table for any additional details. Do not use CAUSE_OF_DEATH_DETAIL.,,
PD,,,,,,Unrelated to Disease or Treatment,The cause of death of the subject is unrelated to the disease or treatment that was given.,,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,TRM_TYPE,Enum,Optional,"If the mortality is treatment related, what type of treatment was involved?",ncit:C173260,_undefined_,_undefined_,_undefined_,"D4CGNote: If multiple treatment types, include one observation per treatment type. | ConditionalStatement: If 'LKSS' = 'Dead' and 'CAUSE_OF_DEATH' = 'Treatment-related mortality'.",,
PD,,,,,,Chemotherapy,The use of synthetic or naturally-occurring chemicals for the treatment of diseases.,ncit:C15632,,,
PD,,,,,,Radiation Therapy,,,,,
PD,,,,,,Immunotherapy,Therapy designed to induce changes in a patient's immune status in order to treat disease.,ncit:C15262,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,CAUSE_OF_DEATH_DETAIL,Enum,Optional,The more granular reason for the CAUSE_OF_DEATH of the subject.,ncit:C168868,_undefined_,_undefined_,_undefined_,"D4CGNote: If multiple cause of death details, include one observation per cause of death detail. | ConditionalStatement: Only fill in this variable if LKSS = ""Dead"".",,
PD,,,,,,Bacterial Infection,"An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.",ncit:C2890,,,
PD,,,,,,Cardiac Disease,"A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.",ncit:C3079,,,
PD,,,,,,Fungal Infection,An infection caused by a fungus.,ncit:C3245,,,
PD,,,,,,Graft Versus Host Disease,"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.",ncit:C3063,,,
PD,,,,,,Hemorrhage,The flow of blood from a ruptured blood vessel.,ncit:C26791,,,
PD,,,,,,"Infection, NOS","The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.",ncit:C128320,,,
PD,,,,,,Multi-Organ Failure,Complete impairment of two or more organs or organ systems.,ncit:C75568,,,
PD,,,,,,Pulmonary Disease,"A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).",ncit:C3198,,,
PD,,,,,,Surgical Complication,"A disease or disorder that occurs during, soon after or as a result of a surgical procedure.",ncit:C164157,,,
PD,,,,,,Viral Infection,Any disease caused by a virus.,ncit:C3439,,,
PD,,,,,,Immunotherapy-Related,An observation that a situation is related to immunotherapy received.,ncit:C168874,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,CAUSE_OF_DEATH_RANKING,Enum,Optional,Assigning a weighted relevance to the cause of death.,ncit:C168932,_undefined_,_undefined_,_undefined_,"D4CGNote: There may be multiple contributory causes of death, but only one primary cause of death. ConditionalStatement: Only fill in this variable if 'LKSS' = 'Dead'.",,
PD,,,,,,Primary,The first significant event which ultimately led to death.,ncit:C99531,,,
PD,,,,,,Contributory,Any adverse event contributing to the cause of death.,ncit:C168948,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Testing,,,,,,,,,,
TD,Vitals And Anthropometrics,,Optional,,,,,,,,
TG,One row per subject per vital or anthropometric measurement,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_MEASUREMENT,Integer,Mandatory,The age (in days) of the subject when the vitals measurement was taken.,ncit:C154628,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,MEASUREMENT_TYPE,Enum,Mandatory,The type of vital sign or anthropomorphic measurement being recorded,ncit:C49672,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Weight,The weight of a subject.,ncit:C81328,,,
PD,,,,,,Height,The vertical measurement or distance from the base to the top of a subject or participant.,ncit:C164634,,,
PD,,,,,,BSA,"A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing.",ncit:C25157,,,
VD,RESULT_NUMERIC,Decimal,Mandatory,The vital sign or anthropomorphic measurement being recorded (numeric).,ncit:C173268,_undefined_,_undefined_,_undefined_,D4CGNote: Only fill in this variable if the available data is a single numeric value.,,
VD,RESULT_UNIT,Enum,Priority,The units used for the vital sign or anthropomorphic measurement being recorded (numeric).,ncit:C49675,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RESULT_NUMERIC' not null.,,
PD,,,,,,kg,"A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.",ncit:C28252,,,
PD,,,,,,cm,"A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch",ncit:C49668,,,
PD,,,,,,m2,"A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.",ncit:C42569,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Testing,,,,,,,,,,
TD,Function Test,,Optional,,,,,,,,
TG,One row per subject per function test result,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_FUNCTION_TEST,Integer,Mandatory,The age (in days) of the subject at the time of the function test.,ncit:C185624,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,TEST,Enum,Mandatory,The function test used on the subject.,ncit:C186304,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"Vestibular, cVEMP",,,,,
PD,,,,,,"Vestibular, VHIT",,,,,
PD,,,,,,"Cochlear, PEAP",,,,,
PD,,,,,,"Cochlear, OEAP",,,,,
PD,,,,,,"Audiogram, NOS",,,,,
VD,LATERALITY,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Right,,,,,
PD,,,,,,Left,,,,,
VD,HZ_FREQUENCY,Enum,Optional,The hertz frequency at which the test is administered.,,_undefined_,_undefined_,_undefined_,"ConditionalStatement: If 'TEST' = 'Audiogram, NOS'.",,
PD,,,,,,500,,,,,
PD,,,,,,1000,,,,,
PD,,,,,,2000,,,,,
PD,,,,,,4000,,,,,
PD,,,,,,8000,,,,,
PD,,,,,,16000,,,,,
VD,RESULT,Enum,Priority,,,_undefined_,_undefined_,_undefined_,"ConditionalStatement: If 'TEST' = 'Vestibular, VHIT'.",,
PD,,,,,,Normal,,,,,
PD,,,,,,Abnormal,,,,,
VD,RESULT_NUMERIC,Decimal,Priority,The numeric result of the function test.,ncit:C185629,_undefined_,_undefined_,_undefined_,,,
VD,RESULT_UNIT,Enum,Optional,The unit of the numeric measurement of the function test.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RESULT_NUMERIC' is not null.,,
PD,,,,,,%,A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).,ncit:C48570,,,
PD,,,,,,dB,,,,,
VD,AVERAGE_LOSS_LOW,Decimal,Optional,,,_undefined_,_undefined_,_undefined_,,,
VD,AVERAGE_LOSS_HIGH,Decimal,Optional,,,_undefined_,_undefined_,_undefined_,,,
VD,GRADE,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"SIOP Boston, Grade 0",20 dB all,,,,
PD,,,,,,"SIOP Boston, Grade 1",>20 dB at >4 kHz,,,,
PD,,,,,,"SIOP Boston, Grade 2",>20 dB at 4 kHz,,,,
PD,,,,,,"SIOP Boston, Grade 3",>20 dB at 2 or 3 kHz,,,,
PD,,,,,,"SIOP Boston, Grade 4",>40 dB at 2 kHz,,,,
PD,,,,,,"Chang, Grade 0","20 dB at 1, 2 and 4 kHz",,,,
PD,,,,,,"Chang, Grade 1a",40 dB at 612 kHz,,,,
PD,,,,,,"Chang, Grade 1b",>20 dB and <40 dB at 4 kHz,,,,
PD,,,,,,"Chang, Grade 2a",40 dB at 4 kHz,,,,
PD,,,,,,"Chang, Grade 2b",">20 and <40 dB at 1, 2 or 3 kHz",,,,
PD,,,,,,"Chang, Grade 3",40 dB at 2 or 3 kHz,,,,
PD,,,,,,"Chang, Grade 4",40 dB at 1 kHz,,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Testing,,,,,,,,,,
TD,Laboratory Test,,Optional,,,,,,,,
TG,One row per subject per lab test result,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_LAB,Integer,Mandatory,The age (in days) of the subject at the time of the laboratory test.,ncit:C172691,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,CATEGORY,Enum,Optional,The category of laboratory test performed on the subject.,ncit:C83017,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Peripheral Blood Analysis,A laboratory analysis of a sample of peripheral blood.,ncit:C173271,,,
PD,,,,,,Bone Marrow Analysis,A laboratory analysis of a sample of bone marrow.,ncit:C173273,,,
PD,,,,,,Cerebrospinal Fluid Analysis,A laboratory analysis of a sample of cerebrospinal fluid.,ncit:C173272,,,
VD,TEST,Enum,Mandatory,"A medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.",ncit:C117142,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Absolute Neutrophil Count,"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).",ncit:C63321,,,
PD,,,,,,Albumin,A quantitative measurement of albumin present in a sample.,ncit:C64431,,,
PD,,,,,,Alkaline Phophatase,A quantitative measurement of alkaline phosphatase present in a sample.,ncit:C64432,,,
PD,,,,,,ALP,A quantitative measurement of alkaline phosphatase present in a sample.,ncit:C64432,,,
PD,,,,,,ALT,A quantitative measurement of alanine aminotransferase present in a sample.,ncit:C64433,,,
PD,,,,,,ANC,"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).",ncit:C63321,,,
PD,,,,,,AST,A quantitative measurement of aspartate aminotransferase present in a sample.,ncit:C64467,,,
PD,,,,,,Calcium,A quantitative measurement of the amount of calcium present in a sample.,ncit:C64488,,,
PD,,,,,,Chloride,A quantitative measurement of the amount of chloride present in a sample.,ncit:C64495,,,
PD,,,,,,Creatinine,A quantitative measurement of the amount of creatinine present in a sample.,ncit:C64547,,,
PD,,,,,,Creatinine Clearance,"The determination of the clearance of endogenous creatinine, used for evaluating the glomerular filtration rate.",ncit:C25747,,,
PD,,,,,,Direct Bilirubin,The bilirubin is bound to glucuronide to form conjugated bilirubin (direct bilirubin). Direct Bilirubin measurement is accomplished by a colorimetric method. Direct Bilirubin in biological fluids reacts with sulfanilic acid at acidic pH to produce a red colored complex. The optical density of produced color has a direct relationship with Direct Bilirubin concentration in the solution.,ncit:C64481,,,
PD,,,,,,EBV DNA,The determination of the amount of Epstein-Barr virus DNA present in a sample.,ncit:C166035,,,MW: Which of these EBV tests are used for tumor samples?
PD,,,,,,EBV IgG,The determination of the amount of Epstein-Barr virus in a biological sample.,ncit:C184675,,,
PD,,,,,,EBV-PCR,,,,,
PD,,,,,,EBV-VCA-IgA-IFT,,,,,
PD,,,,,,EBER,The determination of the amount of Epstein-Barr early antigen present in a sample.,ncit:C96602,,,Epstein-Barr virus (EBV)-encoded small RNAs
PD,,,,,,Eosinophils,The determination of the number of eosinophils in a blood sample.,ncit:C64550,,,
PD,,,,,,Free T3,The determination of the amount of free triiodothyronine present in a sample.,ncit:C74787,,,
PD,,,,,,Free T4,The determination of the amount of free thyroxine present in a sample.,ncit:C74786,,,
PD,,,,,,GGT,A quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample.,ncit:C64847,,,
PD,,,,,,Glucose,The determination of the amount of glucose present in a sample.,ncit:C105585,,,
PD,,,,,,Hemoglobin,A quantitative measurement of the amount of hemoglobin present in a biospecimen.,ncit:C64848,,,
PD,,,,,,Lymphocytes,The determination of the number of lymphocytes in a blood sample.,ncit:C12535,,,
PD,,,,,,Monocytes,The determination of the number of monocytes in a blood sample.,ncit:C64823,,,
PD,,,,,,Neutrophils,A test to determine the number of neutrophils in a sample of blood.,ncit:C51950,,,
PD,,,,,,Platelets,The determination of the number of platelets in a biospecimen.,ncit:C51951,,,
PD,,,,,,Potassium,A quantitative measurement of the amount of potassium present in a sample.,ncit:C64853,,,
PD,,,,,,P16,An indication that CDKN2A-p16 expression has been detected in a sample using immunohistochemical techniques.,ncit:C158943,,,
PD,,,,,,Sialometry,,,,,
PD,,,,,,Sodium,A quantitative measurement of the amount of sodium present in a sample.,ncit:C64809,,,
PD,,,,,,Total Bilirubin,"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.",ncit:C38037,,,
PD,,,,,,TSH,A quantitative measurement of the amount of thyrotropin present in a sample.,ncit:C64813,,,
PD,,,,,,WBC,A test to determine the number of leukocytes in a biospecimen.,ncit:C51948,,,
VD,SPECIMEN,Enum,Optional,"The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances.",ncit:C70713,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Blood,A small volume of blood removed for testing or storage.,ncit:C17610,,,
PD,,,,,,Tumor,The type of material sample taken from a biological entity for tumor findings assessment testing.,ncit:C119940,,,
PD,,,,,,Serum,A sample of serum collected for analysis.,ncit:C178987,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,RESULT,Enum,Priority,The categorical result of the laboratory test.,ncit:C36292,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RESULT_MODIFIER' and 'RESULT_NUMERIC' are null.,,"Per TROD, What does Positive/Negative mean? Results are never Negative per Enis"
PD,,,,,,Positive,"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.",ncit:C35682,,,
PD,,,,,,Negative,"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.",ncit:C38757,,,"Same as ""undetected"" ?"
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,RESULT_TEXT,String,Priority,The string/text result of the laboratory test.,ncit:C36292,_undefined_,_undefined_,_undefined_,"D4CGNote: String result can include anything that is not a single numeric result, i.e. ""Positive"", ""Negative"", ""Present"", ""Absent"", ""Yes"", ""No"", ""Elevated,"" ""Depressed"", ""Above threshold"", ""Below threshold"", ranges, as well as bucketed categories, etc... | ConditionalStatement: If 'RESULT' and 'RESULT_NUMERIC' are null",,
VD,RESULT_NUMERIC,Decimal,Priority,The numeric result of the laboratory test.,ncit:C83320,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RESULT' and 'RESULT_MODIFIER' are null.,,
VD,RESULT_UNIT,Enum,Optional,The unit of the numeric result of the laboratory test.,ncit:C173274,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RESULT_NUMERIC' is not null.,,
PD,,,,,,g,The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.,ncit:C48155,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,COLLECTION_TIME,Decimal,Optional,"The time it takes to collect a sample for a laboratory test depends on the type of test, the patient's condition, and the laboratory's procedures.",,_undefined_,_undefined_,_undefined_,,,"Per TROD, is there a better format to report this?"
,,,,,,,,,,,
,,,,,,,,,,,
DD,Disease Attributes,,,,,,,,,,
TD,Disease Site Assessment,,Priority,,,,,,,,
TG,"One row per subject per evaluation and per lesion (local, regional or metastatic)",,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_DISEASE_SITE_ASSESSMENT,Integer,Mandatory,The age (in days) of the subject at the time of this disease site assessment.,ncit:C174997,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,TUMOR_SUBMITTER_ID,String,Mandatory,The anatomic site of the tumor.,,_undefined_,_undefined_,_undefined_,,,
VD,PRIMARY_TUMOR_SUBMITTER_ID,String,Mandatory,The reference ID of the primary tumor - this ties non-primary tumors back to their appropriate primary tumor.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if disease site is not the primary site.,,
VD,CLASSIFICATION,Enum,Mandatory,The classification of a tumor based primarily on histopathological characteristics.,ncit:C174459,_undefined_,_undefined_,_undefined_,"ConditionalStatement: If 'CLASSIFICATION_STATUS' = 'Present' | ConditionalStatement: If ""SITE"" = ""Nasopharynx""",,
PD,,,,,,Primary,A tumor at the original site of origin.,ncit:C8509,,,
PD,,,,,,Regional,A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.,ncit:C41844,,,
PD,,,,,,Metastatic,A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.,ncit:C14174,,,
PD,,,,,,Local Extension,The spread or growth of a tumor (abnormal mass of tissue) from its initial site of origin into nearby tissues or structures within the same region of the body. Local extension is a characteristic feature of many cancers and is an important consideration in cancer staging and diagnosis.,,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,SITE,Enum,Mandatory,The anatomical site on which the disease is assessed.,ncit:C166232,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Bone,The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.,ncit:C12366,,,
PD,,,,,,Bone Marrow,"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.",ncit:C12431,,,
PD,,,,,,Brain,An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.,ncit:C12439,,,
PD,,,,,,Head and Neck,"For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.",ncit:C12418,,,
PD,,,,,,Liver,"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.",ncit:C12392,,,
PD,,,,,,Lung,"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.",ncit:C12468,,,
PD,,,,,,Lymph Node,A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.,ncit:C12745,,,
PD,,,,,,Nasopharynx,"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.",ncit:C12423,,,
PD,,,,,,Soft Tissue,"A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.",ncit:C12471,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,LATERALITY,Enum,Priority,A qualifier for the side of the body the tumor findings assessment is performed.,ncit:C119931,_undefined_,_undefined_,_undefined_,ConditionalStatement: Priority for applicable sites.,,
PD,,,,,,Left,A finding indicating the tumor location is on the left side of the specimen.,ncit:C160200,,,
PD,,,,,,Right,A finding indicating the tumor location is on the right side of the specimen.,ncit:C160199,,,
PD,,,,,,Bilateral,A finding indicating the tumor location is on the both sides of the specimen.,ncit:C160201,,,
PD,,,,,,Midline,A finding indicating the tumor location is on the midline of the specimen.,ncit:C162614,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,DETECTION_METHOD,Enum,Optional,The method used to detect the extent of the disease involvement.,ncit:C173262,_undefined_,_undefined_,_undefined_,,,MW: Imaging done for tumor assessment vs imaging done to gauge response to treatment.
PD,,,,,,Technetium Bone Scan,Bone scintigraphy (a.k.a. bone scans) is a nuclear medicine (scintigraphic) study that makes use of technetium-99m (commonly Tc-99m-methylene diphosphonate (MDP)) as the active agent.,,,,
PD,,,,,,X-Ray,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,ncit:C38101,,,
PD,,,,,,Endoscopy,,,,,
PD,,,,,,CT Scan,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,ncit:C17204,,,
PD,,,,,,PET Scan,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",ncit:C17007,,,
PD,,,,,,PET-CT,An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.,ncit:C103512,,,"MW: Instanbul - are ""PET-CT"" and ""MRI"" just yes/no variables in your data?"
PD,,,,,,MRI,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",ncit:C16809,,,
PD,,,,,,"Imaging, NOS","Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.",ncit:C17369,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,TISSUE_TYPE,Enum,Optional,"A piece of tissue removed from an organism for examination, analysis, or propagation.",ncit:C119940,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Bone,The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.,ncit:C12366,,,
PD,,,,,,Soft Tissue,"A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.",ncit:C12471,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,MULTIPLICITY,Enum,Optional,This variable indicates if the recorded observation is detailing a single tumor or multiple tumors at a given site.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Single,,,,,
PD,,,,,,Multiple,,,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,DIAMETER1,Decimal,Optional,The longest diameter of the tumor.,ncit:C96684,_undefined_,_undefined_,_undefined_,,,
VD,DIAMETER1_UNIT,Enum,Optional,The unit of measure symbol associated with a biospecimen or tissue fragment dimension.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,cm,"A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.",ncit:C49668,,,
VD,DIAMETER2,Decimal,Optional,The second longest diameter of the tumor.,ncit:C96684,_undefined_,_undefined_,_undefined_,,,
VD,DIAMETER2_UNIT,Enum,Optional,The unit of measure symbol associated with a biospecimen or tissue fragment dimension.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,cm,"A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.",ncit:C49668,,,
VD,DIAMETER3,Decimal,Optional,The third longest diameter of the tumor.,ncit:C96684,_undefined_,_undefined_,_undefined_,,,
VD,DIAMETER3_UNIT,Enum,Optional,The unit of measure symbol associated with a biospecimen or tissue fragment dimension.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,cm,"A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.",ncit:C49668,,,
VD,GTV,Decimal,Optional,Gross Tumor Volume (GTV),,_undefined_,_undefined_,_undefined_,,,"MW: Lyon - Is ""Poids (kg)"" of the tumor itself? KO: [Achibadem].[GTV Lymph nodes] || [Achibadem].[GTV primary tumor] need to be included separately?"
,,,,,,,,,,,
,,,,,,,,,,,
DD,Disease Attributes,,,,,,,,,,
TD,Staging,,Priority,,,,,,,,
TG,One row per subject per staging assessment,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_STAGING,Integer,Mandatory,The age (in days) of the subject at the time of this staging assessment.,ncit:C177359,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,STAGE_SYSTEM,Enum,Mandatory,A systematic method for clinicopathologic evaluation of tumors.,ncit:C18004,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,AJCC,,,,,
VD,STAGE,Enum,Mandatory,"The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.",ncit:C16899,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Stage 1,Invasive cancer confined to the original anatomic site of growth without lymph node involvement.,ncit:C27966,,,
PD,,,,,,Stage 2,"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.",ncit:C28054,,,
PD,,,,,,Stage 2A,"Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)",ncit:C6364,,,
PD,,,,,,Stage 2B,"Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1). pTX: Primary tumor cannot be assessed. N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension. M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000. (AJCC 6th and 7th eds.)",ncit:C6365,,,
PD,,,,,,Stage 3,Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.,ncit:C27970,,,
PD,,,,,,Stage 4,Cancer that has spread to distant anatomic sites beyond its original site of growth.,ncit:C27971,,,
PD,,,,,,Stage 4A,,,,,
PD,,,,,,Stage 4B,,,,,
PD,,,,,,Stage 4C,,,,,
VD,TNM_TUMOR_T,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,T0,Main tumor cannot be found.,,,,
PD,,,,,,T1,Tumor confined to the nasopharynx,,,,Restricted to nasopharynx; extension into nastal cavity; extension into oropharynx without parapharyngeal extension.
PD,,,,,,T2,Tumor extends to soft tissue of oropharynx and/or nasal fossa,,,,
PD,,,,,,T2a,Without paraphyaryngeal extension,,,,
PD,,,,,,T2b,With parapharyngeal extension,,,,
PD,,,,,,T3,Tumor invades bony structures or paranasal sinuses,,,,
PD,,,,,,T4,"Tumor with intracranial extension and/or involvement of cranial nerves, infratemporal fossa, hypopharynx, or orbit",,,,Extension intracranially; extension infiltration of cranial nerves; into fossa infratemporalis; into hypopharynx; into orbita oder; spatium masticatorium.
VD,TNM_NODE_N,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,N0,No regional lymph node metastasis,,,,
PD,,,,,,N1,Unilateral metastasis in lymph node(s) measuring  6 cm in greatest dimension above the supraclavicular fossa,,,,"Ipsilateral LN  6 cm, above caudal border of cricoid cartilage; Ipsilateral LN retropharyngeal  6 cm; Bilateral LN retropharyngeal  6 cm."
PD,,,,,,N2,Bilateral metastasis in lymph node(s) measuring  6 cm in greatest dimension above the supraclavicular fossa,,,,"Bilateral LN  6 cm, above caudal border of cricoid cartilage."
PD,,,,,,N3,Not further subclassifiable: metastasis in a lymph node(s),,,,Metastasis in a lymph node(s) > 6cm and/or below caudal border of cricoid cartilage (regardless of laterality).
PD,,,,,,N3a,>6 cm in greatest dimension,,,,
PD,,,,,,N3b,Extension to the supraclavicular fossa,,,,
VD,TNM_METASTASIS_M,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,M0,A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.,ncit:C48699,,,
PD,,,,,,M1,A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.,ncit:C48700,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Disease Attributes,,,,,,,,,,
TD,Diagnosis,,Priority,,,,,,,,
TG,One row per subject per diagnosis,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_DIAG_ASSESSMENT,Integer,Mandatory,The age (in days) of the subject at the time of this diagnostic assessment.,ncit:C175004,_undefined_,_undefined_,_undefined_,"ConditionalStatement: Mandatory if ""AGE_AT_ENROLLMENT"" is null.",,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,DIAGNOSIS,Enum,Mandatory,"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.",ncit:C15220,_undefined_,_undefined_,_undefined_,,,ICD-O Coding
PD,,,,,,"Squamous Cell Carcinoma, NOS",,icdo:8070/3,,,8070/3 Nasopharyngeal carcinoma
PD,,,,,,"Squamous Cell Carcinoma, Keratinizing, NOS",,icdo:8071/3,,,"8071/3 Squamous cell carcinoma, keratinizing, NOS (WHO Type I)"
PD,,,,,,"Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS",,icdo:8072/3,,,"8072/3 Squamous cell carcinoma, non-keratinizing, NOS (would include Types II and III)"
PD,,,,,,Basaloid Squamous Cell Carcinoma,,icdo:8083/3,,,8083/3 Basaloid squamous cell carcinoma (doesn't have a WHO type number)
VD,REVIEW_SOURCE,Enum,Optional,The type of assessment that was used to review.,ncit:C185324,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Institutional,Local institutional review process at treating institution.,ncit:C185325,,,
PD,,,,,,Central,Conducts reviews on behalf of all study sites that agree to participate in the centralized review process with imaging experts.,ncit:C185326,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,DIAGNOSIS_BASIS,Enum,Optional,The type of diagnosis used for determining the medical condition.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Histological,Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.,ncit:C25526,,,
VD,HISTOLOGIC_FEATURES,Enum,Optional,The observable characteristics and attributes of tissue samples examined under a microscope.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,With Lymphoid Infiltration,,,,,ICD-11 coding
PD,,,,,,Without Lymphoid Infiltration,,,,,"2B6B.0 & XH6705 Squamous cell carcinoma of nasopharynx & Squamous cell carcinoma, keratinizing, NOS"
,,,,,,,,,,,"2B6B.0 & XH4CR9 Squamous cell carcinoma of nasopharynx & Squamous cell carcinoma, non-keratinizing, NOS"
,,,,,,,,,,,2B6B.0 & XH3GS1 Squamous cell carcinoma of nasopharynx & Basaloid squamous cell carcinoma
DD,Disease Attributes,,,,,,,,,,
TD,Disease Characteristics,,Optional,,,,,,,,
TG,One row per subject per observation,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_DISEASE_CHARACTERISTIC,Integer,Mandatory,The age (in days) of the subject at the start of disease assessment.,,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,PERFORMANCE_SCORE,Enum,Optional,"A standard way of measuring the ability of cancer patients to perform ordinary tasks. Scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities. May be used to determine a patient's prognosis, to measure changes in a patients ability to function, or to decide if a patient could be included in a clinical trial. (Source: NCI Dictionary of Cancer Terms)",,_undefined_,_undefined_,_undefined_,,,"Turkey, Istanbul might not have performance scores"
PD,,,,,,"Karnofsky, 100","Normal, no complaints, no evidence of disease.",ncit:C105707,,,
PD,,,,,,"Karnofsky, 90","Able to carry on normal activity, minor signs or symptoms of disease.",ncit:C105709,,,
PD,,,,,,"Karnofsky, 80","Normal activity with effort, some signs or symptoms of disease.",ncit:C105710,,,
PD,,,,,,"Karnofsky, 70","Cares for self, unable to carry on normal activity or able to do active work.",ncit:C105711,,,
PD,,,,,,"Karnofsky, 60","Requires occaisional assistance, but is able to care for most of his needs.",ncit:C105712,,,
PD,,,,,,"Karnofsky, 50",Requires considerable assistance and frequent medical care.,ncit:C105713,,,
PD,,,,,,"Karnofsky, 40","Disabled, requires special care and assistance.",ncit:C105714,,,
PD,,,,,,"Karnofsky, 30","Severely disabled, hospitalization is indicated although death is not imminent.",ncit:C105715,,,
PD,,,,,,"Karnofsky, 20","Hospitalization necessary, very sick, active supportive treatment necessary.",ncit:C105716,,,
PD,,,,,,"Karnofsky, 10","Moribund, fatal processes progressing rapidly.",ncit:C105718,,,
PD,,,,,,"Karnofsky, 0",Dead.,ncit:C105720,,,
PD,,,,,,"Lansky, 100","Fully active, normal.",ncit:C69426,,,
PD,,,,,,"Lansky, 90",Minor restrictions with strenuous physical activity.,ncit:C69425,,,
PD,,,,,,"Lansky, 80","Active, but gets tired more quickly.",ncit:C69424,,,
PD,,,,,,"Lansky, 70","Both greater restriction of, and less time spent in, active play.",ncit:C69423,,,
PD,,,,,,"Lansky, 60","Up and around, but minimal active play; keeps busy with quieter activities.",ncit:C69422,,,
PD,,,,,,"Lansky, 50","Lying around much of the day, but gets dressed; no active play; participates in all quiet play and activities.",ncit:C69421,,,
PD,,,,,,"Lansky, 40",Mostly in bed; participates in quiet activities.,ncit:C70542,,,
PD,,,,,,"Lansky, 30",Stuck in bed; needs help even for quiet play.,ncit:C70541,,,
PD,,,,,,"Lansky, 20",Often sleeping; play is entirely limited to very passive activities.,ncit:C70540,,,
PD,,,,,,"Lansky, 10",Does not play nor get out of bed.,ncit:C70539,,,
PD,,,,,,"Lansky, 0",Unresponsive.,ncit:C70538,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,SYMPTOMS,Enum,Optional,"Was the subject experiencing any physical or mental problems such as headache, fatigue, nausea, or pain? A physical or mental problem that a person experiences that may indicate a disease or condition. Symptoms cannot be seen and do not show up on medical tests.",ncit:C25269,_undefined_,_undefined_,_undefined_,,,"MW: ISPHO - which additional ""presenting symptoms"" should be listed?"
PD,,,,,,Fever,,,,,COG- won't have symptoms here
PD,,,,,,Night Sweats,,,,,
PD,,,,,,Weight Loss,,,,,
PD,,,,,,Headache,,,,,
PD,,,,,,Bleeding,,,,,
PD,,,,,,Hearing Loss,,,,,
PD,,,,,,Adenopathy,,,,,
PD,,,,,,Nasal Congestion,,,,,
VD,CRANIAL_NERVE_INVOLVEMENT,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Treatment,,,,,,,,,,
TD,Medication,,Priority,,,,,,,,
TG,One row per subject per medication administered,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_MEDICATION_START,Integer,Mandatory,The age (in days) of the subject at the start of this medication treatment.,ncit:C172698,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_MEDICATION_END,Integer,Optional,The age (in days) of the subject at the end of this medication treatment.,ncit:C172686,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,MEDICATION,Enum,Mandatory,"A dosage form that contains one or more active and/or inactive ingredients. Medications come in many dosage forms, including tablets, capsules, liquids, creams, and patches. They can also be given in different ways, such as by mouth, by infusion into a vein, or by drops that are put into the ear or eye. The form with the active ingredient is used to prevent, diagnose, treat, or relieve symptoms of a disease or abnormal condition. A medication that does not contain an active ingredient and is used in research studies is called a placebo. Also called drug product.",ncit:C459,_undefined_,_undefined_,_undefined_,"ConditionalStatement: If ""ADMINISTRATION_STATUS"" = ""Medication Administered"".",,
PD,,,,,,Amifostine,"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.",ncit:C488,,,
PD,,,,,,Bleomycin,"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.",ncit:C313,,,
PD,,,,,,Carboplatin,"A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)",ncit:C1282,,,
PD,,,,,,Cisplatin,"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.",ncit:C376,,,
PD,,,,,,Docetaxel,"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)",ncit:C1526,,,
PD,,,,,,Doxorubicin,"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.",ncit:C456,,,
PD,,,,,,Fluorouracil (5FU),"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.",ncit:C505,,,
PD,,,,,,Gemcitabine,"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in ""masked termination"" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.",ncit:C66876,,,
PD,,,,,,Interferon,"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)",ncit:C20493,,,
PD,,,,,,Ipilimumab,"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.",ncit:C2654,,,
PD,,,,,,Methotrexate,"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.",ncit:C642,,,
PD,,,,,,Nivolumab,"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.",ncit:C68814,,,
PD,,,,,,Paclitaxel,"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)",ncit:C1411,,,
PD,,,,,,Pembrolizumab,"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.",ncit:C106432,,,
PD,,,,,,Sodium Thiosulfate,"A water soluble salt and reducing agent that reacts with oxidizing agents. Although its exact mechanism of action is unknown, thiosulfate likely provides an exogenous source of sulfur, thereby hastening the detoxification of cyanide through the enzyme rhodanese (thiosulfate cyanide sulfurtransferase) which converts cyanide to the relatively nontoxic, excretable thiocyanate ion. In addition, this agent neutralizes the reactive alkylating species of nitrogen mustard, thereby decreasing skin toxicity related to nitrogen mustard extravasation. (NCI04)",ncit:C1230,,,
PD,,,,,,Tetrathiomolybdate (TM),"An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.",ncit:C160684,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,ADMINISTRATION_STATUS,Enum,Mandatory,The status of the medication administration.,ncit:C173297,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Medication Administered,An indication that medication was administered.,ncit:C173298,,,
PD,,,,,,Medication Not Administered,An indication that medication was not administered.,ncit:C173299,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,PROTOCOL_MEDICATION,Enum,Optional,Was this medication part of the treatment protocol?,ncit:C175038,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,NUMBER_DOSES,Decimal,Optional,Number of times a dose of the medication was administered between the AGE_AT_MEDICATION_START and AGE_AT_MEDICATION_END values.,ncit:C173293,_undefined_,_undefined_,_undefined_,D4CGNote: Number of doses of chemotherapy agent administered over the indicated start and end time points | D4CGNote: Only fill in this variable if this information is available.,,
VD,TOTAL_DOSE_ADMINISTERED,Decimal,Optional,"Total amount of medication administered between the AGE_AT_MEDICATION_START and AGE_AT_MEDICATION values. Assuming all doses administered are the same amount of medication, this value should be equal to the amount of medication given at each dose multiplied by the number of doses.",ncit:C94394,_undefined_,_undefined_,_undefined_,D4CGNote: Total dose of the chemotherapy agent administered to the subject over the indicated start and end time points. | D4CGNote: Only fill in this variable if this information is available.,,
VD,TOTAL_DOSE_INTENDED,Decimal,Optional,"This is the total amount of medication that was intended to be administered either by trial protocol, by prescription, or other indicator at the time point of AGE_AT_MEDICATION_START. Often, this will be equal to TOTAL_DOSE_ADMINISTERED. If TOTAL_DOSE_ADMINISTERED and TOTAL_DOSE_INTENDED are different, this indicates a deviation from the protocol or plan and may be due to a variety of factors including patient intolerance, patient non-adherence, etc.",ncit:C173294,_undefined_,_undefined_,_undefined_,D4CGNote: Intention-to-treat total dose of the chemotherapy agent over the indicated start and end time points. | D4CGNote: Only fill in this variable if this information is available.,,
VD,TOTAL_DOSE_UNIT,Enum,Optional,The units of the total dose.,ncit:C17395,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'TOTAL_DOSE_ADMINISTERED' and 'TOTAL_DOSE_INTENDED' not null | D4CGNote: Unit for TOTAL_DOSE_ADMINISTERED and TOTAL_DOSE_INTENDED must be the same.,,
PD,,,,,,mg/m2,A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.,ncit:C67402,,,
PD,,,,,,mg/kilo,A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.,ncit:C67401,,,
PD,,,,,,mg,A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.,ncit:C67402,,,
PD,,,,,,IU,"The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.",ncit:C48579,,,
PD,,,,,,IU/m2,A dose calculation unit expressed as a number of arbitrary units of biological activity (International Units) of substance per square meter of body surface area.,ncit:C67378,,,
VD,CYCLE_NUMBER,Integer,Optional,The number of the individual chemotherapeutic cycle.,ncit:C166208,_undefined_,_undefined_,_undefined_,,,Integer?
VD,CYCLES_PLANNED,Integer,Optional,,,_undefined_,_undefined_,_undefined_,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Treatment,,,,,,,,,,
TD,Radiation Therapy,,Priority,,,,,,,,
TG,One row per subject per radiation therapy administration,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_RT_START,Integer,Mandatory,The age (in days) of the subject at the start of this radiation treatment.,ncit:C172695,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_RT_END,Integer,Optional,The age (in days) of the subject at the end of this radiation treatment.,ncit:C172696,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,SITE,Enum,Mandatory,The anatomic site of the radiation therapy.,ncit:C173281,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Nasopharynx,"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.",ncit:C12423,"D4CGNote: CLASSIFICATION = ""Primary""",,
PD,,,,,,Level I Nodes,,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,Level II Nodes,,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,Level III Nodes,,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,Level IV Nodes,,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,Level V Nodes,,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,Retropharyngeal Nodes,,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,"Regional Lymph Nodes, NOS",,,"D4CGNote: CLASSIFICATION = ""Regional""",,
PD,,,,,,Distant Lymph Nodes,An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.,ncit:C12439,"D4CGNote: CLASSIFICATION = ""Metastatic""",,
PD,,,,,,Bone,The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.,ncit:C12366,"D4CGNote: CLASSIFICATION = ""Metastatic""",,
PD,,,,,,Lung,"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.",ncit:C12468,"D4CGNote: CLASSIFICATION = ""Metastatic""",,
PD,,,,,,Liver,"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.",ncit:C12392,"D4CGNote: CLASSIFICATION = ""Metastatic""",,
PD,,,,,,Brain,An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.,ncit:C12439,"D4CGNote: CLASSIFICATION = ""Metastatic""",,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,CLASSIFICATION,Enum,Optional,The classification of a tumor based primarily on histopathological characteristics.,ncit:C174459,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Primary,A tumor at the original site of origin.,ncit:C8509,,,
PD,,,,,,Regional,A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.,ncit:C41844,"D4CGNote: Includes 'PTV2"" and ""PTV3""",,
PD,,,,,,Metastatic,A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.,ncit:C14174,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,LATERALITY,Enum,Optional,The laterality intended for radiation therapy.,ncit:C175523,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Left,A finding indicating the tumor location is on the left side of the specimen.,ncit:C160200|ncit:C25229,,,
PD,,,,,,Right,A finding indicating the tumor location is on the right side of the specimen.,ncit:C160199|ncit:C25228,,,
PD,,,,,,Bilateral,A finding indicating the tumor location is on the both sides of the specimen.,ncit:C160201|ncit:C13332,,,
PD,,,,,,Midline,A finding indicating the tumor location is on the midline of the specimen.,ncit:C162614,,,
VD,DOSE,Decimal,Mandatory,The total radiation dose administered.,ncit:C173282,_undefined_,_undefined_,_undefined_,,,
VD,DOSE_UNIT,Enum,Mandatory,A unit of measurement of the dose of radiation received or absorbed.,ncit:C18068,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,cGy,The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.,ncit:C64693,,,
PD,,,,,,CGE,A unit of relative biological effectiveness of protons equivalent to 60 cobalt gamma rays.,ncit:C128269,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,NUM_FRACTION,Decimal,Optional,The number of divided radiation doses received per day.,ncit:C175034,_undefined_,_undefined_,_undefined_,,,
VD,FRACTION_DOSE,Decimal,Optional,The amount of radiation delivered to the treatment area in a single session or fraction.,,_undefined_,_undefined_,_undefined_,,,
VD,FRACTION_DOSE_UNIT,Enum,Optional,A unit of measurement of the dose of radiation received or absorbed.,ncit:C18068,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Gy,"A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.",ncit:C18063,,,
PD,,,,,,cGy,The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.,ncit:C64693,,,
PD,,,,,,CGE,A unit of relative biological effectiveness of protons equivalent to 60 cobalt gamma rays.,ncit:C128269,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,BOOST_TYPE,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Simultaneous Integrated,"A modification of intensity modulated radiation therapy that allows for the simultaneous delivery of different dose levels to different target volumes within a single treatment fraction. This can result in better sparing of critical structures, more efficient delivery, shorter treatment duration, and better biologic effectiveness.",ncit:C121139,,,
PD,,,,,,Sequential,A specific approach in radiation therapy where a higher dose of radiation (a boost) is delivered to a tumor or a specific area sequentially after an initial course of treatment.,,,,
VD,TREATMENT_VOLUME,Enum,Optional,,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,PTV Low Risk,,,D4CGNote: Use for PTV3,,
PD,,,,,,PTV Intermediate Risk,,,D4CGNote: Use for PTV2,,
PD,,,,,,PTV High Risk,,,D4CGNote: Use for PTV1,,
VD,TECHNIQUE,Enum,Optional,The specific method or approach used to deliver radiation to a targeted area within the body for the treatment of cancer or other medical conditions. Different techniques are employed to maximize the effectiveness of radiation therapy while minimizing damage to surrounding healthy tissues.,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"EBRT, 3D Conformal",A form of external beam radiation therapy (EBRT) in which doctors to sculpt radiation beams to the shape of a tumor and deliver to the tumor from several angles.,ncit:C16035,,,
PD,,,,,,"EBRT, Intensity-Modulated","A form of external beam radiation therapy (EBRT) in which advanced software plans a precise dose of radiation, based on tumor size, shape and location. A computer-controlled device delivers the radiation in sculpted doses that match the 3-D geometrical shape of the tumor, including concave and complex shapes. The intensity of radiation beams can be adjusted across the treatment area in fractioned, separate beams as precision accuracy",ncit:C16135,,,
PD,,,,,,"EBRT, Stereotactic Radiosurgery",A form of external beam radiation therapy (EBRT) in which a high dose of radiation is delivered to a small area in the brain or head from many angles.,ncit:C15358,,,
PD,,,,,,"EBRT, Stereotactic Body","Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.",ncit:C118286,Stereotactic ablative body radiotherapy,,
PD,,,,,,"EBRT, Tomotherapy","A type of external beam radiation therapy in which the radiation is delivered slice-by-slice, providing sequential delivery of radiation to different parts of the tumor. This method differs from other forms of radiation therapy in which the entire tumor volume is irradiated at one time.",ncit:C62731,Helical IMRT,,
PD,,,,,,"EBRT, Pencil Beam Scanning","A precise form of proton therapy that uses an electronically guided scanning system and magnets to deliver a proton beam that is millimeters wide. With this system, beam position and depth can be controlled, allowing for highly precise deposition of radiation to be delivered in all three dimensions of the tumor.",ncit:C165502,D4CGNote: ENERGY_TYPE = Proton,,
PD,,,,,,"EBRT, Double Scattering",,,D4CGNote: ENERGY_TYPE = Proton,,
PD,,,,,,"EBRT, Volume Modulated Arc Therapy",Radiation therapy delivered to the whole volume of target tissue by a single rotation of the linear accelerator gantry.,ncit:C104933,,,
PD,,,,,,"EBRT, NOS","External beam radiation therapy (EBRT), subtype not otherwise specified",,,,[GPOH].[A3.9].[Conventional]
PD,,,,,,Brachytherapy,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",ncit:C15195,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,ENERGY_TYPE,Enum,Optional,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,ncit:C15313,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Photon,A type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator (linac). The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Photon beam radiation therapy is different from proton beam therapy.,ncit:C104914,,,
PD,,,,,,Proton,A type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator (linac). The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Photon beam radiation therapy is different from proton beam therapy.,ncit:C104914,,,
PD,,,,,,Electron,A fundamental particle with a negative charge.,ncit:C40428,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Treatment,,,,,,,,,,
TD,Biopsy And Surgical Procedures,,Optional,,,,,,,,
TG,One row per subject per procedure,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_PROCEDURE,Integer,Mandatory,The age (in days) of the subject at the time of this procedure.,ncit:C175008,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,PROCEDURE,Enum,Mandatory,A categorization of surgical procedures by type or purpose.,ncit:C161601,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Surgery,"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.",ncit:C15329,,,
PD,,,,,,Biopsy,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",ncit:C15189,,,
PD,,,,,,Lymph Node Dissection,,,,,
PD,,,,,,Fine Needle Aspiration,The removal of tissue or fluid with a thin needle for examination under a microscope.,ncit:C15361,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,BIOPSY_TYPE,Enum,Priority,"The removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy. (Source: NCI Dictionary of Cancer Terms)",ncit:C15189,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'PROCEDURE' = 'Biopsy'.,,
PD,,,,,,Core Needle Biopsy,"The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.",ncit:C15680,,,
PD,,,,,,Incisional Biopsy,A surgical procedure in which part of a lesion is removed for microscopic examination.,ncit:C15386,,,
PD,,,,,,Excisional Biopsy,A surgical procedure in which an entire lesion is removed for microscopic examination.,ncit:C15385,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,SURGERY_TYPE,Enum,Priority,A query about the type of resection.,ncit:C186756,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'PROCEDURE' = 'Surgery'.,,"Was RESECTION_TYPE, coordinate with OS"
PD,,,,,,Lymph Node Dissection,,,,,
PD,,,,,,Lung Resection,,,,,
PD,,,,,,Craniofacial Resection,,,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,SITE,Enum,Priority,The anatomical site on which surgery was performed.,ncit:C164323,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Bone,Connective tissue that forms the skeletal components of the body.,ncit:C12366,,,
PD,,,,,,Brain,An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.,ncit:C12439,,,
PD,,,,,,Cervical Nodes,Any of the lymph nodes located in the neck.,ncit:C32298,,,
PD,,,,,,Liver,"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.",ncit:C12392,,,
PD,,,,,,Lung,"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.",ncit:C12468,,,
PD,,,,,,Nasopharynx,,,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,PROTOCOL_PROCEDURE,Enum,Optional,Was this procedure part of the treatment protocol?,ncit:C175038,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Yes,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,No,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,CLASSIFICATION,Enum,Optional,The classification of a tumor based primarily on histopathological characteristics.,ncit:C174459,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Primary,A tumor at the original site of origin.,ncit:C8509,,,
PD,,,,,,Regional,,,,,
PD,,,,,,Metastatic,A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.,ncit:C14174,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,LATERALITY,Enum,Optional,A qualifier for the side of the body the procedure is performed.,ncit:C117526,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Left,Being or located on or directed toward the side of the body to the west when facing north.,ncit:C25229,,,
PD,,,,,,Right,Being or located on or directed toward the side of the body to the east when facing north.,ncit:C25228,,,
PD,,,,,,Bilateral,Affecting both sides of the body or a matched pair of organs.,ncit:C13332,,,
PD,,,,,,Midline,"A medial line, especially the medial line or medial plane of the body (or some part of the body).",ncit:CC81170,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,PROCEDURE_EXTENT,Enum,Optional,"The degree to which the lesion has been cut out, or resected.",ncit:C157443,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Gross Total,"Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.",ncit:C131672,,,
PD,,,,,,Complete Resection,Complete clearance of the tumor with histologically proved negative margins.,ncit:C175027,,,
PD,,,,,,Partial Resection,Surgical removal of a part of a lesion; some portion of the lesion is detectable on post-operative evaluation.,ncit:C131680,,,
PD,,,,,,Equivocal,"A laboratory test result that indicates that a specific disease, condition, or attribute being assessed is not clearly present or absent.",ncit:C178921,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,MARGINS,Enum,Optional,"The edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as positive or involved when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed. (Source: NCI Dictionary of Cancer Terms)",ncit:C41227,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"R0 - Complete Resection, Negative Margins",No detectable presence of residual tumor after treatment,ncit:C139578,,,
PD,,,,,,"R1 - Complete Resection, Positive Margins",Presence of microscopic residual tumor after treatment.,ncit:C139579,,,
PD,,,,,,R2 - Gross Residual Disease,Presence of macroscopic residual tumor after treatment.,ncit:C139580,,,
PD,,,,,,Incomplete Resection,"A response that the resection was incomplete, between 10-90 percent.",ncit:C182305,,,
PD,,,,,,Biopsy Only,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",ncit:C15189,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,PROCEDURE_PURPOSE,Enum,Optional,The reason a procedure is performed.,ncit:C185526,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Surgical Resection of Distant Site,,,,,
PD,,,,,,Initial Diagnostic Procedure,,,,,
PD,,,,,,Second Look Surgery to Attempt Total Resection,,,,,
PD,,,,,,Biopsy of Distant Site for Staging,,,,,
PD,,,,,,Diagnostic Biopsy for Possible Recurrence,,,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Treatment,,,,,,,,,,
TD,Protocol Treatment Modifications,,Optional,,,,,,,,
TG,One row per subject per modification per modification reason per toxicity detail,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_MODIFICATION,Integer,Mandatory,The age (in days) of subject since the protocol treatment modification.,,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,MODIFICATION,Enum,Mandatory,The type of modification used.,ncit:C185632,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Dose Reduction,"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.",ncit:C49505,,,
PD,,,,,,New Agent Addition,The addition of a new drug to a treatment.,ncit:C185633,,,
PD,,,,,,Substitution,The act of putting one thing or person in the place of another.,ncit:C54071,,,
PD,,,,,,Discontinued,"To stop or end, permanently or temporarily.",ncit:C25484,,,
PD,,,,,,Delayed,Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.,ncit:C25476,,,
PD,,,,,,Not Given,There was no excuse provided.,ncit:C106487,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,REASON,Enum,Priority,The reasoning behind a treatment modification.,ncit:C185636,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"Toxicity, NOS",,,,,
PD,,,,,,Hematologic Toxicity,A treatment designed to reduce or prevent damage to the hematologic system due to adverse events from other drug therapies.,ncit:C15474,,,
PD,,,,,,Non-Hematologic Toxicity,A toxicity that impairs or damages other than the hematologic system.,ncit:C185641,,,
PD,,,,,,Surgical Complications,"A disease or disorder that occurs during, soon after or as a result of a surgical procedure.",ncit:C164157,,,
PD,,,,,,Scheduling Issues,A problem scheduling an event.,ncit:C1685642|ncit:C185642,,,
PD,,,,,,Drug Not Available,A particular drug is unavailable.,ncit:C185643,,,
PD,,,,,,Subject Non-Compliance,"Failure of a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment.",ncit:C91752,,,
PD,,,,,,Pre-Existing Organ Dysfunction,Organ dysfunction that was present prior to evaluation.,ncit:C185644,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,MODIFICATION_BASIS,Enum,Optional,The rationale for why an entity or event is changed.,ncit:C93529,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Per Protocol,Subject is receiving treatment based on protocol.,ncit:C181023,,,
PD,,,,,,Clinical Indication,Signs and/or symptoms leading a practitioner to recommend a particular clinical intervention.,ncit:C185637,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,ORIGINAL_AGENT,Enum,Optional,The first agent planned for a therapy.,ncit:C185650,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Amifostine,"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.",ncit:C488,,,
PD,,,,,,Bleomycin,"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.",ncit:C313,,,
PD,,,,,,Carboplatin,"A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)",ncit:C1282,,,
PD,,,,,,Cisplatin,"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.",ncit:C376,,,
PD,,,,,,Docetaxel,"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)",ncit:C1526,,,
PD,,,,,,Doxorubicin,"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.",ncit:C456,,,
PD,,,,,,Fluorouracil (5FU),"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.",ncit:C505,,,
PD,,,,,,Gemcitabine,"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in ""masked termination"" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.",ncit:C66876,,,
PD,,,,,,Interferon,"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)",ncit:C20493,,,
PD,,,,,,Ipilimumab,"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.",ncit:C2654,,,
PD,,,,,,Methotrexate,"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.",ncit:C642,,,
PD,,,,,,Nivolumab,"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.",ncit:C68814,,,
PD,,,,,,Paclitaxel,"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)",ncit:C1411,,,
PD,,,,,,Pembrolizumab,"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.",ncit:C106432,,,
PD,,,,,,Sodium Thiosulfate,"A water soluble salt and reducing agent that reacts with oxidizing agents. Although its exact mechanism of action is unknown, thiosulfate likely provides an exogenous source of sulfur, thereby hastening the detoxification of cyanide through the enzyme rhodanese (thiosulfate cyanide sulfurtransferase) which converts cyanide to the relatively nontoxic, excretable thiocyanate ion. In addition, this agent neutralizes the reactive alkylating species of nitrogen mustard, thereby decreasing skin toxicity related to nitrogen mustard extravasation. (NCI04)",ncit:C1230,,,
PD,,,,,,Tetrathiomolybdate (TM),"An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.",ncit:C160684,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Response,,,,,,,,,,
TD,Subject Response,,Optional,,,,,,,,"MW: ISPHO - ""Relapse -> Outcome"" and imaging studies follow-up?"
TG,One row per subject per response assessment,,,,,,,,,,ML: need to know what system is used. COG did not indicate.
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,"At end of neo-adjuvant, end of combination, end of maintenance"
VD,AGE_AT_RESPONSE,Integer,Mandatory,The age (in days) of the subject at the time of this response assessment.,ncit:C168856,_undefined_,_undefined_,,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,RESPONSE,Enum,Mandatory,"A standard way to measure how well a cancer patient responds to treatment. It is based on whether tumors shrink, stay the same, or get bigger. To use Response Evaluation Criteria In Solid Tumors, there must be at least one tumor that can be measured on x-rays, CT scans, or MRI scans. The types of response a patient can have are a complete response (CR), a partial response (PR), progressive disease (PD), and stable disease (SD). Also called RECIST. (Source: NCI Dictionary of Cancer Terms)",ncit:C50995,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"RECIST, Complete Response",Complete response (CR): no more measurable tissue mass at the primary site and no residual lymphadenopathy of small axis >1 cm.,ncit:C4870,,,EBV as a response method
PD,,,,,,"RECIST, Partial Response","At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.",ncit:C159547,,,
PD,,,,,,"RECIST, Progressive Disease","At least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.",ncit:C159716,,,
PD,,,,,,"RECIST, Stable Disease","Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment.",ncit:C159546,,,
PD,,,,,,"WHO, Complete Response",,,,,
PD,,,,,,"WHO, Partial Response",,,,,
PD,,,,,,"WHO, Progressive Disease",,,,,
PD,,,,,,"WHO, Stable Disease",,,,,
PD,,,,,,"EXPeRT, Complete Response",No more measurable tissue mass at the primary site and no residual lymphadenopathy of small axis >1 cm.,,,,
PD,,,,,,"EXPeRT, Very Good Partial Response",Tumor reduction (cavum + lymphadenopathy) between 80% and 99% or isolated persistence of a thickening of mucosa of the nasopharynx.,,,,
PD,,,,,,"EXPeRT, Partial Response","Reduction of the overall tumor mass (i.e., cavum and lymph nodes) between 50% and 80%.",,,,
PD,,,,,,"EXPeRT, Minor Response",Decrease of the overall tumor mass between 25 and 50%.,,,,
PD,,,,,,"EXPeRT, Stable Disease",Change of the overall tumor mass of +- 25%.,,,,
PD,,,,,,"EXPeRT, Progressive Disease",Tumor mass increase >25% and/or the appearance of distant metastases or new lymphadenopathies.,,,,
PD,,,,,,Very Good Partial Response,"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.",ncit:C123618,,,
PD,,,,,,Partial Response,A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.,ncit:C18058,,,ML: same as partial remission? wait for Tal's data
PD,,,,,,Progressive Disease,A disease process that is increasing in scope or severity.,ncit:C35571,,,
PD,,,,,,Stable Disease,Cancer that is neither decreasing nor increasing in extent or severity.,ncit:C18213,,,
PD,,,,,,Not Evaluable,Unable to be evaluated.,ncit:C62222,,,
PD,,,,,,Not Applicable,Determination of a value is not relevant in the current context.,ncit:C48660,,,
VD,RESPONSE_SYSTEM,Enum,Priority,A standard from which a judgment concerning tumor response to therapy can be established.,ncit:C125932,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,RECIST,"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (""respond""), stay the same (""stable""), or worsen (""progression"") during treatments.",ncit:C49164,,,
PD,,,,,,WHO,A United Nations agency established to coordinate international health activities and to help governments improve health services.,ncit:C75419,,,
PD,,,,,,EXPeRT,A European consensus guideline for the diagnosis and treatment of pediatric NPC developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT).,,,,
VD,RESPONSE_SYSTEM_VERSION,String,Optional,The version of the response criteria system.,ncit:C175042,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'RESPONSE_SYSTEM' is not null.,,
VD,RESPONSE_CATEGORY,Enum,Optional,The category used to assess the response to therapy.,ncit:C173306,_undefined_,_undefined_,_undefined_,,,Include RESPONSE to radiotherapy as well
PD,,,,,,Overall Response,An assessment of the overall response of the disease to the therapy.,ncit:C96613,,,
PD,,,,,,Primary Site Response,The response at a primary site of a disease or condition to treatment.,ncit:C200253,,,
PD,,,,,,Lymph Node Response,"Criteria for the response to treatment in lymph nodes, as a component of global response.",ncit:C159957,,,
PD,,,,,,Metastatic Response,,,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Events,,,,,,,,,,
TD,Adverse Events,,Optional,,,,,,,,
TG,One row per subject per adverse event,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_AE,Integer,Mandatory,The age (in days) of the subject at the onset of this adverse event.,ncit:C172677,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_AE_RESOLVED,Integer,Optional,The age (in days) of the subject when this adverse event was resolved.,ncit:C175043,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Optional,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,ADVERSE_EVENT,Enum,Mandatory,"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",ncit:C41331,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if AE_CODE is not known.,,
PD,,,,,,Anemia,"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.",ncit:C2869,,,
PD,,,,,,Cataract,,,,,
PD,,,,,,CNS Necrosis,,,,,
PD,,,,,,Cranial Nerve Palsy,,,,,
PD,,,,,,Dental Developmental Abnormality,,,,,
PD,,,,,,Dermatitis,,,,,
PD,,,,,,Dysphagia,,,,,
PD,,,,,,Febrile Neutropenia,,,,,
PD,,,,,,Growth Hormone Deficiency,,,,,
PD,,,,,,Hearing Impaired,,,,,
PD,,,,,,Hematuria,,,,,
PD,,,,,,Hoarseness,,,,,
PD,,,,,,Hypopituitarism,,,,,
PD,,,,,,Hypothyroidism,,,,,
PD,,,,,,Mucositis,Inflammation of the mucous membranes.,ncit:C27961,,,
PD,,,,,,Neck Fibrosis,,,,,
PD,,,,,,Neutropenia,A decrease in the number of neutrophils in the peripheral blood.,ncit:C3408,,,
PD,,,,,,Optic Nerve Disorder,,,,,
PD,,,,,,Osteoradionecrosis,Necrosis of bone following exposure to a source of radiation.,ncit:C115459,,,
PD,,,,,,Ototoxicity,Damage to the inner ear as a result of exposure to drugs or chemicals.,ncit:C66929,,,
PD,,,,,,Paresthesia,"A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.",ncit:C143736,,,
PD,,,,,,Psychiatric Disorder,,,,,Any specific psychiatric conditions?
PD,,,,,,Proteinuria,The presence of abnormal amounts of protein in the urine.,ncit:C38012,,,
PD,,,,,,Pulmonary Fibrosis,Toxicity that impairs or damages the lung(s). This condition is often caused by the administration of a pharmaceutical agent that causes damage to the lungs.,ncit:C27994,,,
PD,,,,,,Radiation Caries,,ncit:C177374,,,
PD,,,,,,Renal Toxicity,Toxicity that impairs or damages the kidney. This condition is often caused by the administration of a pharmaceutical agent that causes damage to the kidney.,,,,
PD,,,,,,Retinopathy,,,,,
PD,,,,,,Secondary Malignancy,A primary malignant neoplasm in a patient who has been already diagnosed with a primary malignant neoplasm in another anatomic site.,ncit:C95606,,,
PD,,,,,,Spinal Cord Toxicity,,,,,
PD,,,,,,Stroke,,,,,
PD,,,,,,Tinnitus,,,,,
PD,,,,,,Thrombocytopenia,A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.,ncit:C3036,,,
PD,,,,,,Trismus,,,,,
PD,,,,,,Vertigo,,,,,
PD,,,,,,Vision Decreased,,,,,
PD,,,,,,Xerostomia,,,,,
PD,,,,,,Weight Loss,,,,,
VD,AE_CODE,String,Optional,The code of the adverse event.,ncit:C173313,_undefined_,_undefined_,_undefined_,"ConsortiumNote: For ARAR0031, AE_CODE should be the NCIt term for the selected CTCAE grade.",,
VD,AE_CODE_SYSTEM,Enum,Optional,The coding system used for the AE_CODE,ncit:C168872,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,CTCAE,A standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event.,ncit:C49704,,,
PD,,,,,,RTOG,"A multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient",ncit:C19778,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,AE_CODE_SYSTEM_VERSION,String,Optional,The version of the adverse event grading system.,ncit:C173314,_undefined_,_undefined_,_undefined_,ConditionalStatement: If AE_CODE_SYSTEM not null.,,
VD,GRADE,Enum,Optional,A numeric value corresponding to the degree of severity of an adverse event.,ncit:C166200,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,"CTCAE, Grade 1","An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.",ncit:C41338,,,
PD,,,,,,"CTCAE, Grade 2","An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.",ncit:C41339,,,
PD,,,,,,"CTCAE, Grade 3",An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.,ncit:C41340,,,
PD,,,,,,"CTCAE, Grade 4","Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.",ncit:C41337,,,
PD,,,,,,"CTCAE, Grade 5",The termination of life associated with an adverse event.,ncit:C48275,,,
PD,,,,,,"RTOG, Grade 1/Grade 2",Mild,,,,
PD,,,,,,"RTOG, Grade 3/Grade 4",Serious,,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,ATTRIBUTION,Enum,Optional,A specific identifiable level (defined qualitatively or quantitatively) of probability of adverse event being caused or associated with the product or procedure administration to a patient.,ncit:C41358,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Definite,"Definite adverse event attribution to study product or procedure is established when there is a clear-cut temporal association between product or procedure administration and adverse event, and no other possible cause is present.",ncit:C41356,,,
PD,,,,,,Probable,"Probable adverse event relationship to study product or procedure is defined when there is a clear-cut temporal association between product or procedure administration and adverse event, and a potential alternative etiology of the event is not apparent.",ncit:C41357,,,
PD,,,,,,Possible,"Possible adverse event relationship to study product or procedure is defined when there is less clear temporal association between product or procedure administration and adverse event, and other etiologies of the event are also possible.",ncit:C41359,,,
PD,,,,,,Unlikely,"A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.",ncit:C53257,,,
PD,,,,,,Unrelated,A characteristic used to qualify the adverse event as clearly not related to the medical intervention.,ncit:C53256,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
,,,,,,,,,,,
,,,,,,,,,,,
DD,Events,,,,,,,,,,
TD,Subsequent Malignant Neoplasm,,Optional,,,,,,,,
TG,One row per subject per subsequent malignant neoplasm,,,,,,,,,,
VD,HONEST_BROKER_SUBJECT_ID,String,Mandatory,"The identifier assigned to the subject by the honest broker. An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a ""re-identification code""), however the information linking this re- identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.",ncit:C168949,_undefined_,_undefined_,_undefined_,,,
VD,AGE_AT_SMN,Integer,Mandatory,The age (in days) of subject at the diagnosis of the subsequent malignant neoplasm.,ncit:C168860,_undefined_,_undefined_,_undefined_,,,
VD,TIME_PERIOD_SUBMITTER_ID,String,Mandatory,"This is the SUBMITTER_ID of the time period (defined in the ""Time Period"" table) during which this observation takes place.",,_undefined_,_undefined_,_undefined_,ConditionalStatement: Mandatory if age at observation is not known.,,
VD,SMN_STATUS,Enum,Mandatory,Was the indicated subsequent malignant neoplasm found in the patient?,,_undefined_,_undefined_,_undefined_,,,
PD,,,,,,Present,The affirmative response to a question.,ncit:C49488,,,
PD,,,,,,Absent,The non-affirmative response to a question.,ncit:C49487,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,SMN_SITE,Enum,Priority,SMN Site,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
PD,,,,,,Brain,An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.,ncit:C12439,,,
PD,,,,,,Head and Neck,"For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.",ncit:C12664,,,
PD,,,,,,Thorax,The division of the body lying between the neck and the abdomen.,ncit:C12418,,,
PD,,,,,,Limbs,A body region referring to an upper or lower extremity.,ncit:C12429,,,
PD,,,,,,Upper Abdomen,The portion of the body that lies between the thorax and the pelvis.,ncit:C12767,,,
PD,,,,,,Pelvis,"The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.",ncit:C12799,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,SMN_TYPE,Enum,Priority,SMN Type,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
PD,,,,,,Leukemia,"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.",ncit:C2916,,,
PD,,,,,,Lymphoma,"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.",ncit:C3208,,,
PD,,,,,,Sarcoma,"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.",ncit:C3161,,,
PD,,,,,,Carcinoma,"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.",ncit:C9118,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,
VD,MORPH_CODE,String,Optional,The morphology code describes the cell type of the tumor and its biologic activity.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
VD,MORPH_CODE_TEXT,String,Optional,The display text for MORPH_CODE.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
VD,MORPH_CODE_SYSTEM,Enum,Optional,The coding system for the code used in MORPH_CODE.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
PD,,,,,,ICD-O,A code for the primary site of a tumor being reported using either ICD-O-2 or ICD-O-3.,ncit:C160903,,,
VD,MORPH_CODE_SYSTEM_VERSION,String,Optional,The version of the coding system indicated in MORPH_CODE_SYSTEM.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
VD,TOP_CODE,String,Optional,The topography code describes the site of origin of the neoplasm.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
VD,TOP_CODE_TEXT,String,Optional,The display text for TOP_CODE.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
VD,TOP_CODE_SYSTEM,Enum,Optional,The coding system for the code used in TOP_CODE.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
PD,,,,,,ICD-O,A code for the primary site of a tumor being reported using either ICD-O-2 or ICD-O-3.,ncit:C160903,,,
VD,TOP_CODE_SYSTEM_VERSION,String,Optional,The version of the coding system indicated in TOP_CODE_SYSTEM.,,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
VD,SMN_FIELD,Enum,Optional,The location of the subsequent malignant neoplasm related to the prior radiation field.,ncit:C175044,_undefined_,_undefined_,_undefined_,ConditionalStatement: If 'TREATMENT_RELATED' = 'Yes'. | ConditionalStatement: If 'SMN_STATUS' = 'Present'.,,
PD,,,,,,In XRT Field,Within the confines of the radiation field.,ncit:C175045,,,
PD,,,,,,Margin of XRT Field,The outer aspect of the x-ray therapy field.,ncit:C185695,,,
PD,,,,,,Out of XRT Field,Outside the confines of the radiation field.,ncit:C175046,,,
PD,,,,,,Unknown,Reported as unknown by the data contributor.,ncit:C17998,,,
PD,,,,,,Not Reported,Not provided or available.,ncit:C43234,,,